I would expect that a MNTA collaboration to develop and commercialize one or more FoB’s for the US market would have the following features:
• $40-75M of up-front cash per compound.
• A roughly 50/50 split of development costs.
• Full payment by partner of commercialization costs.
• A roughly 50/50 split of net profits.
• Indemnification by partner for potential legal liability arising from the collaboration.
• An option for ex-US development that would trigger an up-front licensing fee if exercised.
The above features might also apply to a collaboration for so-called biobetters that would be developed using the traditional BLA pathway; however, I think MNTA’s focus will be on the abbreviated regulatory pathway for FoB’s set forth in the 2010 healthcare law (#msg-48581353).
JMHO, FWIW
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.